Bremelanotide: A Specific Indication and Specific Risks
AXON Research Institute • AXON Peptide affiliation
Educational draft • Scientific + legal review pending
Silent film with full on-screen captions. Conceptual illustrations, not molecular structures.

Bremelanotide, also known as PT-141, is a melanocortin receptor agonist. Its approved US product, Vyleesi, has a specific sexual-health indication. The label covers acquired, generalized hypoactive sexual desire disorder in premenopausal women under defined conditions. It is not an approval for general sexual-performance enhancement. Two randomized, placebo-controlled trials assessed desire and associated distress. Nausea was common, and the label includes important warnings about blood pressure and skin pigmentation. Clinical evidence for the approved product does not validate a differently formulated spray or research vial. The population, diagnostic criteria, route, and safety restrictions remain essential parts of interpreting the findings.

END CARD
Research explained. Not medical advice. Sources and limitations in the accompanying transcript.

SOURCES
[1] Vyleesi prescribing information, revised March 2024
https://vyleesi.com/docs/Vyleesi-Full-Prescribing-Information.pdf
Official US prescribing information and trial summaries

EVIDENCE LIMITATIONS
The indication excludes low desire due to another medical or psychiatric condition, relationship problems, or drug effects.
The label does not indicate Vyleesi for men, postmenopausal women, or sexual-performance enhancement.
This short script is not the complete label. Uncontrolled hypertension or known cardiovascular disease are labeled contraindications.
Evidence for the approved injection is not proof for an intranasal product or a research vial.

TOPIC INVENTORY PROVENANCE (not reused audiovisual media)
Bremelanotide: A Specific Indication and Specific Risks